Fat Loss Peptides: Mechanisms, Evidence, and What Practitioners Need to Know

“Fat loss peptides” is a category that spans a wide evidence range — from drugs with Phase 3 outcomes trials to research compounds with no human data. Before evaluating any specific compound, the mechanism matters. Because different peptides affect fat loss through fundamentally different pathways, and understanding those pathways tells you something real about who should use what, and when.

---

The Four Mechanisms

1. GLP-1 / GIP Receptor Agonism — Appetite and Metabolic Regulation

The GLP-1 pathway produces weight loss primarily through appetite suppression, not thermogenesis or direct fat cell action. GLP-1 receptors in the hypothalamus reduce food-seeking behavior. Slowed gastric emptying extends satiety. The result is sustained caloric deficit through behavioral change driven by biology — not willpower.

The GIP addition in tirzepatide appears to act synergistically. GIP receptors are present in adipose tissue and may directly influence fat storage and mobilization, which likely explains why tirzepatide outperforms semaglutide despite similar GLP-1 activity.

Bottom line: This mechanism is appetite-led. The weight loss is real and large, but it requires continuous drug exposure. Discontinuation data (STEP 4 trial) shows significant weight regain, confirming the effect is pharmacological, not curative.

2. GH Secretagogue Activity — Lipolysis and Body Composition

Growth hormone is directly lipolytic — it activates hormone-sensitive lipase in adipocytes, mobilizing stored fat for oxidation. GH also promotes nitrogen retention, meaning fat loss under GH influence tends to preserve or build lean mass simultaneously. This makes GH secretagogues mechanistically distinct from GLP-1s: they change body composition rather than simply reducing total weight.

GHRH analogs (like CJC-1295, tesamorelin) stimulate the pituitary to release GH in pulses consistent with normal physiological rhythm. GHRPs (like ipamorelin) act on ghrelin receptors to amplify GH release. Combined, they produce additive to synergistic GH elevation.

Bottom line: GH secretagogues are body composition tools. They won’t produce the 15–20% weight reduction that GLP-1s achieve in obesity trials. What they can produce is preferential visceral fat reduction with muscle preservation — a different endpoint that’s clinically meaningful for a different patient population.

3. Direct Lipolytic Fragment Action — Adipocyte Targeting

AOD-9604 represents a distinct category. It’s the C-terminal fragment of growth hormone (amino acids 177–191), modified to improve stability, that retains the fat-mobilizing properties of GH without the anabolic effects (insulin resistance, IGF-1 elevation). The idea was to isolate the lipolytic benefit cleanly.

The mechanism is sound. Rodent data is consistently positive — meaningful fat reduction without weight-independent toxicity. The human story is more complicated: a Phase 3 obesity trial with 7 mg oral dosing did not reach primary endpoints for weight loss. The compound subsequently received FDA GRAS status for use in functional foods, which is a different regulatory category and is often misrepresented as proof of efficacy.

Bottom line: The mechanism is real. The human efficacy evidence at practical doses is not established. This is a compound where the biology is more convincing than the clinical data.

4. NNMT Inhibition — Metabolic Reprogramming

5-Amino-1MQ operates at the intersection of the NAD+ pathway and fat metabolism. NNMT (nicotinamide N-methyltransferase) is an enzyme overexpressed in adipose tissue, particularly in obesity. It consumes SAM (the primary methyl donor) and degrades NAD+ precursors — effectively suppressing the cellular machinery that drives fat oxidation.

Blocking NNMT in animal models produces striking results: significant fat mass reduction, preserved lean mass, improved insulin sensitivity, and increased energy expenditure — all without caloric restriction. The mechanism resembles a pharmacological version of caloric restriction or CR mimetics.

Human data: none yet. The studies that generated excitement are rodent and cell-based. The translation to humans is biologically plausible but unproven.

Bottom line: Genuinely interesting biology, genuine absence of human evidence. For practitioners, this is a “watch carefully” compound, not a prescribing recommendation.

---

The Compounds, Evidence-Graded

Tesamorelin — Strong Evidence, Narrow Indication

The only GH secretagogue with FDA approval. Approved for HIV-associated lipodystrophy, where it reduces visceral fat by 15–20% over 26 weeks. Phase II trials for NASH in the general population are ongoing.

The evidence base is clean: human trials, approved indication, established dosing. The limitation is the narrow label — off-label use for visceral adiposity in metabolically healthy patients exists but lacks the same evidence depth.

Evidence grade: Strong (within approved indication)
→ Tesamorelin monograph

Semaglutide — Strong Evidence, Broad Application

15–17% body weight reduction in STEP trials. 20% cardiovascular risk reduction in SELECT. The most evidence-rich weight loss compound available.

Evidence grade: Strong
→ Semaglutide monograph

Tirzepatide — Strong Evidence, Highest Efficacy

20.9% average weight loss at 15 mg (SURMOUNT-1). Best weight loss efficacy of any approved drug.

Evidence grade: Strong
→ Tirzepatide monograph

CJC-1295 / Ipamorelin — Moderate Evidence, Restricted Access

Human pharmacokinetic and GH-stimulation data exists for both. Body composition outcomes are supported by indirect evidence and clinical observation. No purpose-designed fat loss RCTs.

Access has narrowed significantly following FDA compounding restrictions. Practitioners using these compounds are operating off-label with research peptides in most contexts.

Evidence grade: Moderate
→ CJC-1295 monograph | Ipamorelin monograph

AOD-9604 — Preliminary Evidence

Sound mechanism. Failed Phase 3. Significant rodent data. No approved therapeutic use.

Evidence grade: Preliminary
→ AOD-9604 monograph

5-Amino-1MQ — Preliminary Evidence

Compelling preclinical data. No human trials. Mechanism biologically plausible.

Evidence grade: Preliminary
→ 5-Amino-1MQ monograph

---

Matching Mechanism to Patient

Primary obesity, significant BMI:
GLP-1 receptor agonists are the answer. The magnitude of effect is unmatched and the evidence is unambiguous. Tirzepatide for maximum efficacy; semaglutide where CV outcomes data matters now.

Metabolic syndrome, visceral adiposity, normal or near-normal BMI:
Tesamorelin (if you need an approved track record) or GH secretagogues (where accessible) are mechanistically better suited. These patients don’t need appetite suppression — they need preferential visceral fat mobilization.

Body recomposition — losing fat while preserving or building muscle:
GH secretagogues over GLP-1s. GLP-1-driven weight loss produces meaningful lean mass loss alongside fat loss. GH secretagogues preserve lean tissue.

Research-motivated patients, longevity-focused practice:
AOD-9604 and 5-Amino-1MQ have plausible biology and appear low-risk. Informed consent is the standard — patients need to understand they’re participating in n=1 experiments with no established human efficacy baseline.

---

What Practitioners Often Miss

GLP-1s don’t directly burn fat. They reduce caloric intake. The fat loss is downstream of behavioral change driven by pharmacology. This matters clinically: patients who compensate with liquid calories, or whose appetite suppression fades at plateau, will not get the full STEP trial result.

GH secretagogues don’t produce dramatic weight loss. If a patient’s primary complaint is “I weigh too much,” GH secretagogues aren’t the first-line answer. If the complaint is “my waist measurement is increasing despite normal weight” or “I’m losing muscle,” that’s the right patient.

The research peptide market conflates mechanism with evidence. A compound having a plausible fat-burning mechanism is not the same as it being proven to burn fat in humans. AOD-9604 is the case study: the mechanism is real, the Phase 3 missed, and the compound is still marketed as though the mechanism is the proof.

---

The fat loss peptide landscape is more nuanced than the market suggests — and more hopeful than pure skeptics acknowledge. The GLP-1s are genuinely transformative. The GH secretagogues have real but narrower utility. The research-stage compounds deserve attention without premature claims.

Know the mechanism. Know the evidence. Prescribe accordingly.